The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.

BACKGROUND & AIMS Glucagon-like peptide-2 (GLP-2) is an intestinal hormone that acts through unknown pathways to induce intestinal growth. We investigated the role of the insulin-like growth factors (IGF-1 and IGF-2) as mediators of GLP-2-enhanced growth in the murine intestine. METHODS IGF-1 expression and secretion were determined in GLP-2-responsive primary intestinal cultures treated with GLP-2. Parameters of intestinal growth were assessed in wild-type (CD1, Igf1(+/+) and Igf2+), heterozygous (Igf1(+/-)), and null (Igf1(-/-) and Igf2(-P)) mice treated chronically with saline, GLP-2, IGF-1, or R-Spondin1. RESULTS GLP-2 increased IGF-1 messenger RNA expression and IGF-1 secretion in intestinal cultures and increased expression of IGF-1 messenger RNA in mouse small intestine in vivo. Igf1(+/+) and Igf2+ mice responded to .1 microg/g(-1) per day(-1) GLP-2 with increased intestinal weights, morphometric parameters, and proliferative indices. In contrast, Igf1(-/-) mice were unresponsive to the same dose of GLP-2, failing to demonstrate changes in intestinal weight, morphometry, or proliferation. However, a significant effect of 1 microg/g(-1) per day(-1) GLP-2 was observed in Igf1(-/-) mice, but only in terms of small intestinal weight when normalized for body weight. Furthermore, Igf2(-P) mice demonstrated a partially impaired response in terms of small intestinal growth. Both Igf1(-/-) and Igf2(-P) mice exhibited normal-enhanced intestinal growth in response to IGF-1 and/or R-Spondin1. CONCLUSIONS GLP-2 enhances intestinal IGF-1 expression and secretion, and IGF-1 is required for small and large intestinal growth in response to GLP-2. These findings identify IGF-1 as an essential mediator of the intestinotropic actions of GLP-2.

[1]  J. Scolapio.  Short bowel syndrome: recent clinical outcomes with growth hormone. , 2006, Gastroenterology.

[2]  Takeshi Oshima,et al.  Mitogenic Influence of Human R-Spondin1 on the Intestinal Epithelium , 2005, Science.

[3]  J. Holst,et al.  Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients , 2005, Gut.

[4]  D. Drucker,et al.  Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. , 2005, Gastroenterology.

[5]  J. Holst,et al.  Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[6]  J. Holst,et al.  GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors , 2005, Regulatory Peptides.

[7]  C. Potten,et al.  Teduglutide ([Gly2]GLP‐2) protects small intestinal stem cells from radiation damage , 2004, Cell proliferation.

[8]  A. Theiss,et al.  Growth Factors in Inflammatory Bowel Disease: The Actions and Interactions of Growth Hormone and Insulin-Like Growth Factor-I , 2004, Inflammatory bowel diseases.

[9]  P. Brubaker,et al.  Nutrient, neural and endocrine control of glucagon-like peptide secretion. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[10]  L. Wallace,et al.  Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[11]  D. Ney,et al.  Postreceptor resistance to exogenous growth hormone exists in the jejunal mucosa of parenterally fed rats. , 2004, The Journal of nutrition.

[12]  S. Ashley,et al.  Effect of GLP-2 on mucosal morphology and SGLT1 expression in tissue-engineered neointestine. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[13]  J. Holst,et al.  GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. , 2003, Gastroenterology.

[14]  P. Brubaker,et al.  Glucagon-Like Peptide-2 and Common Therapeutics in a Murine Model of Ulcerative Colitis , 2003, Journal of Pharmacology and Experimental Therapeutics.

[15]  D. Ney,et al.  IGF-I augments resection-induced mucosal hyperplasia by altering enterocyte kinetics. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  J. Holst,et al.  Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[17]  J. Slack,et al.  Structural-proliferative units and organ growth: effects of insulin-like growth factor 2 on the growth of colon and skin , 2003, Development.

[18]  Adrian V. Lee,et al.  Local insulin-like growth factor-II mediates prolactin-induced mammary gland development. , 2003, Molecular endocrinology.

[19]  P. Brubaker,et al.  Role of leptin in the regulation of glucagon-like peptide-1 secretion. , 2003, Diabetes.

[20]  H. Okano,et al.  Candidate markers for stem and early progenitor cells, Musashi‐1 and Hes1, are expressed in crypt base columnar cells of mouse small intestine , 2003, FEBS letters.

[21]  J. Fagin,et al.  Mesenchymal IGF-I overexpression: paracrine effects in the intestine, distinct from endocrine actions. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[22]  G. Adams.  Invited Review: Autocrine/paracrine IGF-I and skeletal muscle adaptation. , 2002, Journal of applied physiology.

[23]  A. Hubbs,et al.  IGF‐I, IGF‐II, and IGF‐receptor‐1 transcript and IGF‐II protein expression in myostatin knockout mice tissues , 2002, Muscle & nerve.

[24]  M. Gillingham,et al.  Resection upregulates the IGF-I system of parenterally fed rats with jejunocolic anastomosis. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[25]  R. Lea,et al.  Beta-actin--an unsuitable internal control for RT-PCR. , 2001, Molecular and cellular probes.

[26]  M. Bjerknes,et al.  Modulation of specific intestinal epithelial progenitors by enteric neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Goodlad,et al.  Proglucagon-Derived Peptides in Intestinal Epithelial Proliferation , 2001, Digestive Diseases and Sciences.

[28]  R. Playford,et al.  Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats , 2001, Gut.

[29]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[30]  K. Rex,et al.  The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[31]  D. Greiner,et al.  Thymic expression of insulin‐related genes in an animal model of autoimmune type 1 diabetes , 2001, Diabetes/metabolism research and reviews.

[32]  O. Dirsch,et al.  Insulin‐like growth factor I and truncated keratinocyte growth factor accelerate healing of left‐sided colonic anastomoses , 2001, The British journal of surgery.

[33]  R. Tarnuzzer,et al.  Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. , 2000, The Journal of endocrinology.

[34]  J. Holst,et al.  GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[35]  B. Yusta,et al.  Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. , 2000, Endocrinology.

[36]  B. Yusta,et al.  Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. , 2000, Gastroenterology.

[37]  P. Yang,et al.  Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse , 2000, Gut.

[38]  A. Hassan,et al.  Insulin-like Growth Factor II Supply Modifies Growth of Intestinal Adenoma in ApcMin/+ Mice , 2000 .

[39]  M. Schwartz,et al.  Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. , 2000, Journal of pediatric surgery.

[40]  B. Yusta,et al.  Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. , 1999, American journal of physiology. Endocrinology and metabolism.

[41]  C. Bondy,et al.  Igf1 promotes longitudinal bone growth by insulin‐like actions augmenting chondrocyte hypertrophy , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  S. Grinstein,et al.  Identification of Glucagon-like Peptide-2 (GLP-2)-activated Signaling Pathways in Baby Hamster Kidney Fibroblasts Expressing the Rat GLP-2 Receptor* , 1999, The Journal of Biological Chemistry.

[43]  M. Adamo,et al.  Investigation of Insulin-Like Growth Factor (IGF)-I and Insulin Receptor Binding and Expression in Jejunum of Parenterally Fed Rats Treated with IGF-I or Growth Hormone1. , 1999, Endocrinology.

[44]  A B West,et al.  Myofibroblasts. II. Intestinal subepithelial myofibroblasts. , 1999, American journal of physiology. Cell physiology.

[45]  D. Podolsky,et al.  Growth factors in inflammatory bowel disease. , 1999, Inflammatory bowel diseases.

[46]  W. MacNaughton,et al.  GLP-2 augments the adaptive response to massive intestinal resection in rat. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[47]  T. Adrian,et al.  An increase in mucosal insulin-like growth factor II content in postresectional rat intestine suggests autocrine or paracrine growth stimulation. , 1998, Scandinavian journal of gastroenterology.

[48]  B. Evers,et al.  Glucagon-like peptide 2 is a potent growth factor for small intestine and colon , 1998, Journal of Gastrointestinal Surgery.

[49]  C. Cheeseman.  Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. , 1997, American journal of physiology. Regulatory, integrative and comparative physiology.

[50]  D. Drucker,et al.  Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[51]  D. Drucker,et al.  Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV , 1997, Nature Biotechnology.

[52]  D. Drucker,et al.  Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. , 1997, The American journal of physiology.

[53]  D. Drucker,et al.  Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. , 1997, The American journal of physiology.

[54]  D. Ney,et al.  GH elevates serum IGF-I levels but does not alter mucosal atrophy in parenterally fed rats. , 1997, The American journal of physiology.

[55]  D. Drucker,et al.  Biological determinants of intestinotrophic properties of GLP-2 in vivo. , 1997, The American journal of physiology.

[56]  A. D'ercole,et al.  Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. , 1997, Gastroenterology.

[57]  D. Drucker,et al.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Potten,et al.  Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. , 1995, Gut.

[59]  M. Ulshen,et al.  Regulation and localization of the insulin-like growth factor system in small bowel during altered nutrient status. , 1995, The American journal of physiology.

[60]  C. Graham,et al.  Disproportionate growth in mice with Igf-2 transgenes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. Ryan,et al.  Determination of the histological distribution of insulin like growth factor 1 receptors in the rat gut. , 1993, Gut.

[62]  L. Powell-Braxton,et al.  IGF-I is required for normal embryonic growth in mice. , 1993, Genes & development.

[63]  L. Powell-Braxton,et al.  Inactivation of the IGF‐I Gene in Mice Results in Perinatal Lethality , 1993, Annals of the New York Academy of Sciences.

[64]  R. Dowling,et al.  Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone. , 1993, Gastroenterology.

[65]  F. Ballard,et al.  Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats. , 1992, The Journal of endocrinology.

[66]  Jon S Thompson,et al.  Short bowel syndrome. , 1996, Clinics in perinatology.

[67]  N. Wright,et al.  Morphometry and cell proliferation in endoscopic biopsies: evaluation of a technique. , 1991, Gastroenterology.

[68]  A. Efstratiadis,et al.  Parental imprinting of the mouse insulin-like growth factor II gene , 1991, Cell.

[69]  A. Efstratiadis,et al.  A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting , 1990, Nature.

[70]  P. Brubaker.  Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. , 1988, Endocrinology.

[71]  E. Adashi,et al.  Insulin-like growth factor-I as an amplifier of follicle-stimulating hormone action: studies on mechanism(s) and site(s) of action in cultured rat granulosa cells. , 1988, Endocrinology.

[72]  H Cheng,et al.  The crypt cycle. Crypt and villus production in the adult intestinal epithelium. , 1987, Biophysical journal.

[73]  V. Han,et al.  Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. , 1987, Science.

[74]  B. Moats-Staats,et al.  Somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues. , 1986, The Journal of biological chemistry.

[75]  Hideyuki Okano,et al.  Identification of a putative intestinal stem cell and early lineage marker; musashi-1. , 2003, Differentiation; research in biological diversity.

[76]  Christopher S Potten,et al.  The intestinal epithelial stem cell. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[77]  D. Le Roith,et al.  Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. , 2001, Annual review of physiology.

[78]  B. Yusta,et al.  Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. , 2001, Cancer research.

[79]  D. Drucker,et al.  Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. , 2000, American journal of physiology. Endocrinology and metabolism.

[80]  B. Yusta,et al.  Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[81]  P. Lund.  IGFs and the Digestive Tract , 1999 .

[82]  J. Holst,et al.  Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. , 1998, Scandinavian journal of gastroenterology.

[83]  J. Wallace,et al.  Continuous 14 day infusion of IGF-II increases the growth of normal female rats, but exhibits a lower potency than IGF-I. , 1995, The Journal of endocrinology.

[84]  D. Drucker,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Circulating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2* , 2022 .